Therapy Name | Palbociclib + Tamoxifen |
Therapy Description |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Palbociclib | Ibrance | PD0332991 | CDK4/6 Inhibitor 8 | Ibrance (palbociclib) is a selective inhibitor of cyclin-dependent kinase 4 (CDK4) and 6 (CDK6) (PMID: 19874578). Ibrance (palbociclib) is approved in combination with an aromatase inhibitor in postmenopausal patients with ER-positive, ERBB2 (HER2)-negative metastatic breast cancer, and in combination with Faslodex (fulvestrant) in patients with ER-positive, ERBB2 (HER2)-negative metastatic breast cancer (FDA.gov). |
Tamoxifen | Nolvadex | ICI-46474 | Hormone Antineoplastics 5 | Nolvadex (tamoxifen) is a selective estrogen receptor modulator (SERM), which decreases DNA synthesis and cell growth (NCI Drug Dictionary). Nolvadex (tamoxifen) is FDA approved for breast cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|---|---|---|---|
NCT02668666 | Phase II | Palbociclib + Tamoxifen | Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer | Recruiting |
NCT03691493 | Phase II | Palbociclib + Letrozole Palbociclib + Tamoxifen Fulvestrant + Palbociclib Anastrozole + Palbociclib Exemestane + Palbociclib | Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (ASPIRE) | Recruiting |